Published in BMJ on January 19, 2002
Contribution of primary care to health systems and health. Milbank Q (2005) 37.91
Hospital bed utilisation in the NHS, Kaiser Permanente, and the US Medicare programme: analysis of routine data. BMJ (2003) 7.50
Building the national health information infrastructure for personal health, health care services, public health, and research. BMC Med Inform Decis Mak (2003) 2.85
Why general practitioners use computers and hospital doctors do not--Part 1: incentives. BMJ (2002) 2.82
Commentary: competition made them do it. BMJ (2002) 2.38
Commentary: same price, better care. BMJ (2002) 2.36
Can the NHS learn from US managed care organisations? BMJ (2004) 2.21
Rehospitalisation after birth hospitalisation: patterns among infants of all gestations. Arch Dis Child (2005) 2.21
Making the NHS more like Kaiser Permanente. BMJ (2004) 2.11
Questioning the claims from Kaiser. Br J Gen Pract (2004) 2.10
Association of population and practice factors with potentially avoidable admission rates for chronic diseases in London: cross sectional analysis. J R Soc Med (2006) 1.83
Should the NHS follow the American way? BMJ (2005) 1.72
Using industrial processes to improve patient care. BMJ (2004) 1.70
Health services research. BMJ (2003) 1.60
Transforming medical care: case study of an exemplary, small medical group. Ann Fam Med (2006) 1.56
Assessing the evolution of primary healthcare organizations and their performance (2005-2010) in two regions of Québec province: Montréal and Montérégie. BMC Fam Pract (2010) 1.53
Education and debate: Reconfiguring health systems. BMJ (2002) 1.51
Lessons for the NHS from Kaiser Permanente. BMJ (2003) 1.44
Learning from Kaiser (part 2). Is integration the answer? Br J Gen Pract (2004) 1.41
Diabetes management in the USA and England: comparative analysis of national surveys. J R Soc Med (2006) 1.36
Getting more for their dollar: Kaiser v the NHS. Working knowledge would have been needed for comparison. BMJ (2002) 1.36
Screening of older community-dwelling people at risk for death and hospitalization: the Assistenza Socio-Sanitaria in Italia project. J Am Geriatr Soc (2007) 1.31
Integrated care pilot in north-west London: a mixed methods evaluation. Int J Integr Care (2013) 1.14
Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q (2009) 1.12
Moving towards true integration. BMJ (2005) 1.11
What Does a Shoulder MRI Cost the Consumer? Clin Orthop Relat Res (2016) 1.07
Internet infrastructures and health care systems: a qualitative comparative analysis on networks and markets in the British National Health Service and Kaiser Permanente. J Med Internet Res (2002) 1.06
Getting more for their dollar: Kaiser v the NHS. Price adjustments falsify comparison. BMJ (2002) 1.04
New providers in UK health care. BMJ (2004) 1.03
Learning from abroad or policy tourism? Br J Gen Pract (2004) 1.02
Is the Kaiser Permanente model superior in terms of clinical integration?: a comparative study of Kaiser Permanente, Northern California and the Danish healthcare system. BMC Health Serv Res (2010) 1.02
Moderately premature infants at Kaiser Permanente Medical Care Program in California are discharged home earlier than their peers in Massachusetts and the United Kingdom. Arch Dis Child Fetal Neonatal Ed (2006) 1.00
Money can't buy you satisfaction. BMJ (2005) 0.97
Powerlessness, control, and complexity: the experience of family physicians in a group model HMO. Ann Fam Med (2004) 0.97
Something is amiss in Denmark: a comparison of preventable hospitalisations and readmissions for chronic medical conditions in the Danish Healthcare system and Kaiser Permanente. BMC Health Serv Res (2011) 0.94
Integrating public health into local healthcare governance in quebec: challenges in combining population and organization perspectives. Healthc Policy (2009) 0.91
Getting more for their dollar: Kaiser v the NHS. Use of OECD database has led to incorrect conclusions. BMJ (2002) 0.89
Towards an organisation-wide process-oriented organisation of care: a literature review. Implement Sci (2011) 0.89
A retrospective analysis of health systems in Denmark and Kaiser Permanente. BMC Health Serv Res (2008) 0.89
Comparative health systems research among Kaiser Permanente and other integrated delivery systems: a systematic literature review. Perm J (2014) 0.88
Performance measures of the specialty referral process: a systematic review of the literature. BMC Health Serv Res (2011) 0.87
What can the UK and US health systems learn from each other? BMJ (2005) 0.86
Developing an active implementation model for a chronic disease management program. Int J Integr Care (2013) 0.85
The continuing saga of emergency room overcrowding: are we aiming at the right target? Healthc Policy (2010) 0.83
An agenda for healthcare and information simulation. Health Care Manag Sci (2005) 0.82
Assessment and management of obesity in childhood and adolescence. Nat Rev Gastroenterol Hepatol (2011) 0.82
Constructing taxonomies to identify distinctive forms of primary healthcare organizations. ISRN Family Med (2013) 0.80
The effect of an active implementation of a disease management programme for chronic obstructive pulmonary disease on healthcare utilization--a cluster-randomised controlled trial. BMC Health Serv Res (2013) 0.80
Integrated care bridges the care gap. Int J Integr Care (2002) 0.80
Commentary: funding is not the only factor. BMJ (2002) 0.79
Introduction to the postanaesthetic care unit. Perioper Med (Lond) (2013) 0.78
Hospital bed utilisation in the NHS and Kaiser Permanente: debate about Kaiser needs transparency and hard evidence. BMJ (2004) 0.78
Are non-attenders a concern for primary care practice? Isr J Health Policy Res (2013) 0.77
Getting more for their dollar: Kaiser v the NHS. Like should be compared with like. BMJ (2002) 0.77
Oh NHS, thou art sick. The NHS' main problem may be overpoliticisation. BMJ (2002) 0.77
Getting more for their dollar: Kaiser v the NHS. Kaiser may be model of American success or aberration. BMJ (2002) 0.77
Patient-experienced effect of an active implementation of a disease management programme for COPD - a randomised trial. BMC Fam Pract (2013) 0.77
Getting more for their dollar: Kaiser v the NHS. United States is paying more and getting less. BMJ (2002) 0.77
Social organization of self-management support of persons with diabetes: a health systems comparison. Scand J Prim Health Care (2012) 0.76
Self-management support to people with type 2 diabetes - a comparative study of Kaiser Permanente and the Danish Healthcare System. BMC Health Serv Res (2012) 0.76
Measuring the performance of urban healthcare services: results of an international experience. J Epidemiol Community Health (2007) 0.75
Achieving Kaiser Permanente quality. Health Care Manage Rev (2016) 0.75
Darzi's review of quality of care in the NHS. BMJ (2008) 0.75
Efficiency in the NHS. J R Soc Med (2002) 0.75
Authors' reply to getting more for their dollar: Kaiser v the NHS. BMJ (2002) 0.75
The epistemic explanation of government failure and the UK National Health Service. HEC Forum (2005) 0.75
Does managed care lead to better or worse quality of care? Health Aff (Millwood) (1997) 6.17
Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ (2000) 3.79
Americans' views on health policy: a fifty-year historical perspective. Health Aff (Millwood) (2001) 3.72
Comparing health system performance in OECD countries. Organization for Economic Cooperation and Development. Health Aff (Millwood) (2001) 3.03
Acute myocardial infarction in women: contribution of treatment variables to adverse outcome. Am Heart J (2000) 2.97
Managed care in transition. N Engl J Med (2001) 2.85
Managed care: the US experience. Bull World Health Organ (2000) 2.69
Quality of care for coronary heart disease in two countries. Health Aff (Millwood) (2001) 2.46
Reevaluation of capitation contracting in New York and California. Health Aff (Millwood) (2001) 2.45
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A (2011) 3.23
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem (2011) 1.94
Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem (2009) 1.87
Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci U S A (2002) 1.65
3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem (2012) 1.40
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A (2012) 1.26
Moving towards true integration. BMJ (2005) 1.11
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother (2012) 1.08
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers. J Med Chem (2014) 1.00
Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines. J Med Chem (2012) 0.98
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. J Med Chem (2013) 0.94
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. J Med Chem (2012) 0.88
Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities. J Pept Sci (2010) 0.87
Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering. ACS Chem Neurosci (2010) 0.86
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorg Med Chem (2013) 0.85
Antimalarial activity of pyrroloiminoquinones from the Australian marine sponge Zyzzya sp. J Med Chem (2012) 0.85
Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity. J Med Chem (2013) 0.83
Novel orally active antimalarial thiazoles. J Med Chem (2011) 0.82
Structure-activity relationship studies of pyrrolone antimalarial agents. ChemMedChem (2013) 0.82
Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. Malar J (2011) 0.81
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1. J Med Chem (2014) 0.80
Pyridyl benzamides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei. J Med Chem (2014) 0.79
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium. J Med Chem (2014) 0.79
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models. Drug Des Devel Ther (2013) 0.79
Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Future Med Chem (2013) 0.78
2,4-Diaminothienopyrimidines as orally active antimalarial agents. J Med Chem (2014) 0.77
Antimalarial pyrido[1,2-a]benzimidazoles. J Med Chem (2011) 0.76
3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis. Eur J Med Chem (2013) 0.75
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle. J Med Chem (2016) 0.75
A boost to service and quality. California addresses the ills of healthcare with selective technology investments. Healthc Inform (2003) 0.75